Telisotuzumab vedotin
Antibody-drug conjugate
From Wikipedia, the free encyclopedia
Telisotuzumab vedotin, sold under the brand name Emrelis, is an antibody drug conjugate used for the treatement of non-small cell lung cancer.[1][2] Telisotuzumab vedotin is a c-Met-directed antibody and microtubule inhibitor conjugate.[1] It was developed by AbbVie.[3]
 | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | c-Met |
| Clinical data | |
| Trade names | Emrelis |
| Other names | ABBV-399, telisotuzumab vedotin-tllv |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a625080 |
| License data | |
| Routes of administration | Intravenous infusion |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| UNII | |
| KEGG | |
The most common adverse reactions include peripheral neuropathy, fatigue, decreased appetite, and peripheral edema.[2] The most common grade 3 or 4 laboratory abnormalities include decreased lymphocytes, increased glucose, increased alanine aminotransferase, increased gamma glutamyl transferase, decreased phosphorus, decreased sodium, decreased hemoglobin, and decreased calcium.[2]
Telisotuzumab vedotin was approved for medical use in the United States in May 2025.[2][4] The US Food and Drug Administration considers it to be a first-in-class medication.[5][6]
Medical uses
Adverse effects
The most common adverse reactions include peripheral neuropathy, fatigue, decreased appetite, and peripheral edema.[2] The most common grade 3 or 4 laboratory abnormalities include decreased lymphocytes, increased glucose, increased alanine aminotransferase, increased gamma glutamyl transferase, decreased phosphorus, decreased sodium, decreased hemoglobin, and decreased calcium.[2]
History
Efficacy was evaluated in the LUMINOSITY study (NCT03539536), a multi-center, open label, multi-cohort trial.[2] The trial included 84 participants with epidermal growth factor receptor wild-type, non-squamous non-small cell lung cancer with high c-Met protein overexpression who had received prior systemic therapy.[2] The benefits and side effects of telisotuzumab vedotin were evaluated in one clinical trial of 168 participants with non-squamous, EGFR wild-type non-small cell lung cancer with high c-Met protein overexpression who had received one to three prior systemic treatments.[4] The US Food and Drug Administration (FDA) granted accelerated approval to telisotuzumab vedotin based predominantly on evidence from one clinical trial (LUMINOSITY/NCT03539536) of 168 participants with non-squamous, epidermal growth factor receptor (EGFR) wild-type non-small cell lung cancer with c Met protein overexpression who had received prior systemic therapy, including 19 participants from the United States.[4] The trial was conducted at 119 sites across 23 countries in North America, Europe, Asia, the Middle East, and Oceania.[4] There were 84 participants with non-squamous, EGFR wild-type non-small cell lung cancer with high c-Met protein overexpression who had received prior systemic therapy.[4]
The FDA granted the application for telisotuzumab vedotin priority review and breakthrough therapy designations.[2]
Society and culture
Legal status
Telisotuzumab vedotin was approved for medical use in the United States in May 2025.[2][3]
Names
Telisotuzumab vedotin is the international nonproprietary name.[7]
Telisotuzumab vedotin is sold under the brand name Emrelis.[2]
